These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 23924792

  • 1. Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.
    Piao H, Kuan CT, Chandramohan V, Keir ST, Pegram CN, Bao X, Månsson JE, Pastan IH, Bigner DD.
    MAbs; 2013; 5(5):748-62. PubMed ID: 23924792
    [Abstract] [Full Text] [Related]

  • 2. Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo.
    Wikstrand CJ, He XM, Fuller GN, Bigner SH, Fredman P, Svennerholm L, Bigner DD.
    J Neuropathol Exp Neurol; 1991 Nov; 50(6):756-69. PubMed ID: 1748882
    [Abstract] [Full Text] [Related]

  • 3. GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice.
    Kato Y, Kuan CT, Chang J, Kaneko MK, Ayriss J, Piao H, Chandramohan V, Pegram C, McLendon RE, Fredman P, Månsson JE, Bigner DD.
    Biochem Biophys Res Commun; 2010 Jan 01; 391(1):750-5. PubMed ID: 19944071
    [Abstract] [Full Text] [Related]

  • 4. The presence of foetal ganglioside antigens 3'-isoLM1 and 3'6'-isoLD1 in both glioma tissue and surrounding areas from human brain.
    von Holst H, Nygren C, Boström K, Collins VP, Fredman P.
    Acta Neurochir (Wien); 1997 Jan 01; 139(2):141-5. PubMed ID: 9088372
    [Abstract] [Full Text] [Related]

  • 5. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.
    Kuan CT, Wakiya K, Keir ST, Li J, Herndon JE, Pastan I, Bigner DD.
    Int J Cancer; 2011 Jul 01; 129(1):111-21. PubMed ID: 20824708
    [Abstract] [Full Text] [Related]

  • 6. Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies.
    Wikstrand CJ, Fredman P, Svennerholm L, Bigner DD.
    Prog Brain Res; 1994 Jul 01; 101():213-23. PubMed ID: 7518092
    [Abstract] [Full Text] [Related]

  • 7. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
    Clin Cancer Res; 2013 Sep 01; 19(17):4717-27. PubMed ID: 23857604
    [Abstract] [Full Text] [Related]

  • 8. Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo.
    Wikstrand CJ, Longee DC, McLendon RE, Fuller GN, Friedman HS, Fredman P, Svennerholm L, Bigner DD.
    Cancer Res; 1993 Jan 01; 53(1):120-6. PubMed ID: 8416736
    [Abstract] [Full Text] [Related]

  • 9. Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro.
    Wikstrand CJ, Fredman P, McLendon RR, Svennerholm L, Bigner DD.
    Mol Chem Neuropathol; 1994 Jan 01; 21(2-3):129-38. PubMed ID: 7522005
    [Abstract] [Full Text] [Related]

  • 10. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors.
    Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.
    Int J Cancer; 2013 May 15; 132(10):2339-48. PubMed ID: 23115013
    [Abstract] [Full Text] [Related]

  • 11. Monoclonal antibodies to malignant human gliomas.
    Wikstrand CJ, Fredman P, Svennerholm L, Humphrey PA, Bigner SH, Bigner DD.
    Mol Chem Neuropathol; 1992 Oct 15; 17(2):137-46. PubMed ID: 1384525
    [Abstract] [Full Text] [Related]

  • 12. The glioma-associated gangliosides 3'-isoLM1, GD3 and GM2 show selective area expression in human glioblastoma xenografts in nude rat brains.
    Hedberg KM, Mahesparan R, Read TA, Tysnes BB, Thorsen F, Visted T, Bjerkvig R, Fredman P.
    Neuropathol Appl Neurobiol; 2001 Dec 15; 27(6):451-64. PubMed ID: 11903928
    [Abstract] [Full Text] [Related]

  • 13. Sialyllactotetraosylceramide, a ganglioside marker for human malignant gliomas.
    Fredman P, von Holst H, Collins VP, Granholm L, Svennerholm L.
    J Neurochem; 1988 Mar 15; 50(3):912-9. PubMed ID: 3339365
    [Abstract] [Full Text] [Related]

  • 14. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.
    Ho M, Kreitman RJ, Onda M, Pastan I.
    J Biol Chem; 2005 Jan 07; 280(1):607-17. PubMed ID: 15491997
    [Abstract] [Full Text] [Related]

  • 15. Reasonable design of antibody mimetics for targeting glioma and small cell lung cancer.
    Jiang T, Zhang L, Wang J, Li X.
    Eur J Cancer Prev; 2009 Nov 07; 18(6):431-5. PubMed ID: 19741543
    [Abstract] [Full Text] [Related]

  • 16. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
    Choi BD, Gedeon PC, Kuan CT, Sanchez-Perez L, Archer GE, Bigner DD, Sampson JH.
    J Immunol Methods; 2013 Sep 30; 395(1-2):14-20. PubMed ID: 23806556
    [Abstract] [Full Text] [Related]

  • 17. Gangliosides associated with primary brain tumors and their expression in cell lines established from these tumors.
    Fredman P.
    Prog Brain Res; 1994 Sep 30; 101():225-40. PubMed ID: 8029453
    [Abstract] [Full Text] [Related]

  • 18. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display.
    Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I.
    Proc Natl Acad Sci U S A; 1996 Dec 10; 93(25):14815-20. PubMed ID: 8962138
    [Abstract] [Full Text] [Related]

  • 19. A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas.
    Zhang Y, Sun X, Huang M, Ke Y, Wang J, Liu X.
    Drug Des Devel Ther; 2015 Dec 10; 9():2947-59. PubMed ID: 26089644
    [Abstract] [Full Text] [Related]

  • 20. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
    Dunn RD, Weston KM, Longhurst TJ, Lilley GG, Rivett DE, Hudson PJ, Raison RL.
    Immunotechnology; 1996 Sep 10; 2(3):229-40. PubMed ID: 9373315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.